Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05758948). This is a study registration, not published results. Lead sponsor: Hellenic Cooperative Oncology Group. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 101 participants (ESTIMATED). Conditions: Metastatic Breast Cancer. Interventions: DIAGNOSTIC_TEST: NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue. Primary outcome measures: Number of participants with somatic pathogenic variants in denovo metastatic breast cancer , up to 12 months; Number of participants with germline pathogenic variants in denovo metastatic breast cancer , up to 12 months. Brief summary: To determine somatic and germline pathogenic variants in patients with denovo metastatic breast cancer in order to map the molecular/genetic characteristics of DN- MBC aiming in comprehending the biology and highlighting potential novel treatment options for the disease.